23andMe Bets a Nonprofit Model Can Revive Its DNA Platform
Bloomberg’s Emily Chang profiles Anne Wojcicki’s attempt to rebuild 23andMe after a collapse from a $5.7bn public-market valuation to bankruptcy. Wojcicki argues the company’s mistake was trying to be understood as a consumer, diagnostics and therapeutics business at once, but says its genetic database still has social and scientific value if recast as a nonprofit “open science platform.” The interview frames the comeback around the unresolved problem that made 23andMe valuable and vulnerable: persuading people to trust it with highly sensitive DNA data.
Bloomberg Originals·Jun 3, 2026·15 min read
